FDA Announces Voluntary Recall of Chlorthalidone Blood Pressure Tablets
A voluntary nationwide recall is underway for 11,460 bottles of chlorthalidone tablets, a prescription medication commonly used to treat high blood pressure and fluid retention. According to the Food and Drug Administration, the recall covers 25 mg chlorthalidone tablets with an expiration date of April 2027.
The recall was initiated June 5 by Inventia Healthcare Limited, the India-based manufacturer of the tablets, and remains ongoing, according to the FDA’s recall notice. The medication was distributed in the United States by Rising Pharma Holdings, based in East Brunswick, New Jersey.
The FDA said the recall was prompted by “failed dissolution specifications.” Dissolution testing measures how quickly a drug’s active ingredient is released from a tablet or capsule in liquid. The test is used to help assess whether a medication performs consistently and meets quality standards.
Chlorthalidone is classified as a diuretic. Health systems, including the Cleveland Clinic, describe the drug as helping the kidneys remove excess salt and fluid from the blood through urine. It is prescribed to help manage high blood pressure and may also be used to reduce swelling associated with heart, kidney or liver disease.
The recall applies to two bottle sizes. Bottles containing 100 tablets have the batch code RISA24001, while bottles containing 1,000 tablets have the batch code RISB24002. Both affected batches carry the April 2027 expiration date.
Patients who use chlorthalidone should check their prescription bottles for the listed batch codes and expiration date. As with any prescription medication, patients should consult their pharmacist or health care provider before making changes to how they take the drug.
Requests for comment were sent to Inventia Healthcare and Rising Pharma Holdings. The FDA’s recall page continues to list the recall as active. Updates may appear on FDA channels.